Merck, a German drugmaker, revealed on Wednesday that it has finalized a deal to purchase the UK-headquartered Verona Pharma ...

If you’ve been brushing off persistent fatigue frequent headaches or unexplained weight changes your body might be telling ...

Verona Pharma plc (NASDAQ:VRNA) is one of the 11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds.

The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre.

Stocks are slightly higher on Wall Street as the Trump administration seeks to win more deals with global trading partners.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.

T-Mobile US Inc. has rolled back policies related to diversity, equity, and inclusion to appease the chairman of the Federal ...

Substantial challenges characterise the management of chronic obstructive pulmonary disease (COPD), including a progressively ...

Health-care companies rose as deal activity offset more health-insurance controversy. Merck struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup with the chronic obstructive ...

A rally in big tech stocks led Wall Street to a higher close, lifting the Nasdaq to another all-time high. The S&P 500 rose 0 ...

Merck said Wednesday it would buy COPD drugmaker Verona Pharma for $10 billion. The news sent Verona stock flying.